Related Experiment Video
Updated: Mar 1, 2026
Isolation of Cortical Microglia with Preserved Immunophenotype and Functionality From Murine Neonates
Published on: January 30, 2014
Pharmacological Modulation of Functional Phenotypes of Microglia in Neurodegenerative Diseases
1BK21 Plus KNU Biomedical Convergence Program, Department of Pharmacology, Brain Science & Engineering Institute, School of Medicine, Kyungpook National UniversityDaegu, South Korea.
Abstract:
Microglia are the resident innate immune cells of the central nervous system that mediate brain homeostasis maintenance. Microglia-mediated neuroinflammation is a hallmark shared by various neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, and multiple sclerosis. Numerous studies have shown microglial activation phenotypes to be heterogeneous; however, these microglial phenotypes can largely be categorized as being either M1 or M2 type. Although the specific classification of M1 and M2 functionally polarized microglia remains a topic for debate, the use of functional modulators of microglial phenotypes as potential therapeutic approaches for the treatment of neurodegenerative diseases has garnered considerable attention. This review discusses M1 and M2 microglial phenotypes and their relevance in neurodegenerative disease models, as described in recent literature. The modulation of microglial polarization toward the M2 phenotype may lead to development of future therapeutic and preventive strategies for neuroinflammatory and neurodegenerative diseases. Thus, we focus on recent studies of microglial polarization modulators, with a particular emphasis on the small-molecule compounds and their intracellular target proteins.
Insights
Microglia, the brain's immune cells, can be polarized into M1 or M2 types. Modulating microglia towards the M2 phenotype shows promise for treating neurodegenerative diseases like Alzheimer's.
Area of Science:
- Neuroscience
- Immunology
- Cell Biology
Background:
- Microglia are key innate immune cells in the central nervous system, crucial for maintaining brain homeostasis.
- Microglia-mediated neuroinflammation is implicated in neurodegenerative diseases such as Alzheimer's, Parkinson's, and multiple sclerosis.
- Microglial activation is heterogeneous, often classified into M1 (pro-inflammatory) and M2 (anti-inflammatory/repair) phenotypes, though this classification is debated.
Purpose of the Study:
- To review the roles of M1 and M2 microglial phenotypes in neurodegenerative disease models.
- To explore the therapeutic potential of modulating microglial polarization for treating neurodegenerative diseases.
- To highlight recent studies on microglial polarization modulators, focusing on small molecules and their targets.
Main Methods:
- Literature review of recent studies on microglial phenotypes in neurodegenerative diseases.
- Analysis of research on therapeutic strategies targeting microglial polarization.
- Focus on small-molecule compounds and their intracellular targets as modulators.
Main Results:
- Microglial phenotypes (M1/M2) are relevant to neurodegenerative disease pathogenesis.
- Modulating microglial polarization towards the M2 phenotype is a promising therapeutic avenue.
- Small-molecule compounds targeting intracellular proteins are being investigated as M2 polarization inducers.
Conclusions:
- Targeting microglial polarization represents a potential therapeutic strategy for neuroinflammatory and neurodegenerative diseases.
- Further research into microglial polarization modulators, particularly small molecules, is warranted.
- Shifting microglia to an M2 phenotype may offer future therapeutic and preventive benefits.
